Inoviv Snapshot
Our mission is to generate novel molecular insights that transform drug development and healthcare globally. We deliver highly accurate, fully quantitative and definitive targeted biomarker analysis to accelerate the development of life-changing treatments.
We are a team of passionate individuals using innovative science and technology to push the boundaries of proteomics and make a meaningful impact on drug development and healthcare globally.
Our mission is to generate novel molecular insights that transform drug development and healthcare globally. Considering that 60% of therapeutics don’t work and over 92% of clinical trials fail, the losses to the patient and drug development communities are staggering. Inoviv is changing the landscape with our novel proteomics solutions, offered as a service, effectively translating discovery findings to actionable targeted assays, applicable in clinical trial settings. We do this by using our unique ability to rapidly develop novel quantitative assays in regulated environments at low to high-plex, providing a unique molecular signature of each patient’s disease, using mass spectrometry as our core technology, supporting end-to-end service from sample intake, to preparation, to development, to bioinformatics processing. As we work with clients using Inoviv’s proprietary pre-validated panels as well as the development of bespoke multiplexed biomarker offerings, we are reshaping how research into therapeutics is conducted.
Key info:
- Founded in 2018
- Currently over 30 employees across the UK, USA and Spain (Q4 2024)
- VC-backed
Our mission is to generate novel molecular insights that transform drug development and healthcare globally. Considering that 60% of therapeutics don’t work and over 92% of clinical trials fail, the losses to the patient and drug development communities are staggering. Inoviv is changing the landscape with our novel proteomics solutions, offered as a service, effectively translating discovery findings to actionable targeted assays, applicable in clinical trial settings. We do this by using our unique ability to rapidly develop novel quantitative assays in regulated environments at low to high-plex, providing a unique molecular signature of each patient’s disease, using mass spectrometry as our core technology, supporting end-to-end service from sample intake, to preparation, to development, to bioinformatics processing. As we work with clients using Inoviv’s proprietary pre-validated panels as well as the development of bespoke multiplexed biomarker offerings, we are reshaping how research into therapeutics is conducted.
Key info:
- Founded in 2018
- Currently over 30 employees across the UK, USA and Spain (Q4 2024)
- VC-backed
